Evotec AG and Haplogen GmbH have entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (COPD). Further financial terms were not disclosed. The companies began collaborating in 2012 and have since built a portfolio of pulmonary therapeutic programs based on the drug discovery platforms and know-how of both companies. The target-based approach will no...